# Hellenic Institute for the Study of Sepsis: Phase 3 study started recruiting, 398 planned (Sepsis)

**Score:** 85/100

| Field | Value |
|---|---|
| Sponsor | Hellenic Institute for the Study of Sepsis |
| Sponsor type | Academic and hospital |
| Study | THE ROLE OF PANCREATIC STONE PROTEIN (PSP) AND PSP-GUIDED EARLY MEROPENEM TREATMENT TO MITIGATE SEPSIS RISK AT THE EMERGENCY DEPARTMENT: THE PROMISE DOUBLE BLIND, PHASE III, RANDOMIZED CONTROLLED CLINICAL TRIAL |
| NCT ID | NCT07813767 |
| Phase | Phase 3 |
| Status | recruiting |
| Conditions | Sepsis |
| Intervention types | drug |
| Target enrollment | 398 |
| Site countries | Greece |
| Posted | 2026-09-10 |
| Planned start | 2026-10-01 |
| Event | Started recruiting |
| Event date | 2026-10-01 |
| Last update posted | 2026-11-03 |

## Why this score
- Posted in the last two weeks.
- Just started recruiting: sites, recruitment and supply are active.
- Phase 3: multi-site, larger budget.
- 398 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07813767). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.